Dr Martens Docs.L : HSBS Slashes Target Price Amid Ongoing Challenges

HSBC has reduced its target price for Dr. Martens (DOCS.L) to 75p from 85p, reflecting the company's ongoing struggles. The iconic British bootmaker faces mounting pressure to improve its financial performance, with a projected 20% decline in first-half revenue for fiscal 2025. Despite these challenges, Dr. Martens maintains its full-year guidance and plans to implement cost-saving measures of £20-25 million, to be realized from fiscal 2026. The company is also focusing on revitalizing its US market presence through a new marketing strategy. This price target adjustment follows HSBC's recent downgrade of Dr. Martens to "Hold" from "Buy".

 

Source: Reuters, World Footwear, MarketScreener